Data Converter Market Size worth $8.28 Billion, Globally, by 2028 - Exclusive Report by The Insight Partners
November 10, 2023 11:45 ET
|
The Insight Partners
Pune, India., Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to a new report published by The Insight Partners on “Data Converter Market Size and Forecast (2022–2028), Global and Regional Share,...
November is Pancreatic Cancer Awareness Month
November 08, 2023 04:00 ET
|
EnGeneIC
SYDNEY, Australia and NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pancreatic ductal adenocarcinoma (PDAC), which accounts for >90% of pancreatic tumors, is one of the most lethal malignancies and...
ADC Therapeutics nimmt an der Jefferies London Healthcare Conference teil
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Schweiz, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass Ameet Mallik, Chief Executive Officer, auf der Jefferies London Healthcare Conference am...
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics Announces Date of Third Quarter 2023 Financial Results Conference Call
October 31, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023 07:00 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30...
Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies
October 11, 2023 04:00 ET
|
Oxford BioTherapeutics
Oxford, UK and San Jose, Calif., 11 October 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
October 03, 2023 02:00 ET
|
Oxford BioTherapeutics
BI 764532 is an investigational T-cell engager that redirects T cells towards cancer cells expressing the DLL3 proteinDLL3 was discovered using OBT’s proprietary OGAP® drug discovery platformFast...
MacroGenics to Participate in Upcoming Investor Conferences
August 31, 2023 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Aug. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...